Dysfunction of the autonomic nervous system (ANS) is a characteristic feature of patients with synucleinopathies, a group of neurodegenerative diseases caused by the abnormal accumulation of misfolded phosphorylated a-synuclein (aSyn) in neurons, glia, or both. Converging evidence indicates that abnormal aSyn spreads from cell to cell in a prion-like fashion, [1] [2] [3] and that different types of aSyn assemblies with different structural characteristics called strains 4, 5 may account for the different clinical phenotypes given that they determine the nerve cell type and the regions of the nervous system that are affected. 4 In patients with Parkinson's disease (PD), dementia with Lewy bodies (DLB) and pure autonomic failure (PAF) aggregates of misfolded aSyn accumulate in the neuronal soma and throughout axons, called Lewy bodies (LB) and Lewy neurites, and peripheral autonomic neurons are always affected. In these patients, neurodegeneration usually progresses slowly with only a minor impact on survival. 6 In patients with multiple system atrophy (MSA), a rare and devastating disease, aSyn accumulates primarily in oligodendroglia, although neurons are also affected. 7, 8 Autonomic dysfunction is very
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severe, but, in contrast to PD, DLB, and PAF (known as LB disorders), peripheral autonomic neurons are typically spared in MSA. The disease progresses much more rapidly than PD, with an average survival of 9 years from symptom onset. 9, 10 Autonomic dysfunction in synucleinopathies occurs at all stages of the disease and occasionally is its only manifestation. 11 Symptoms of autonomic dysfunction are among the most debilitating and reduce quality of life in affected patients. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, nonpharmacological approaches, and pathophysiologybased drug therapy are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with PD and other synucleinopathies, summarize the nonpharmacological and pharmacological therapeutic strategies, and provide practical advice and management algorithms.
CHALLENGES IN CLINICAL TRIALS OF AUTONOMIC DYSFUNCTION IN PD
Clinical trials for the treatment of symptoms of autonomic dysfunction are challenging. Despite the high prevalence of autonomic dysfunction in patients with PD, only a few therapeutic options are backed by large, randomized, placebo-controlled trials. 12 In spite of its high prevalence, autonomic dysfunction is frequently underdiagnosed in patients with PD and other synucleinopathies. The natural history of autonomic dysfunction in PD and related disorders is still poorly understood (e.g., do orthostatic hypotension [OH] or constipation worsen, or remain stable over time?). The lack of precise data on the occurrence and variability of autonomic abnormalities in these patients hampers the ability to detect clinically meaningful outcomes and contribute to difficulties when powering a clinical trial.
For instance, in the case of clinical trials of midodrine and droxidopa for neurogenic OH (nOH), assembling a large cohort of patients required the involvement of multiple recruiting sites. [13] [14] [15] To enhance recruitment, the trial population was heterogeneous, including not only patients with PD, but also DLB, MSA, PAF, and, occasionally, other rare disorders causing nOH such as dopamine-beta hydroxylase deficiency. Although all these patients had nOH, the pathophysiology differs among them. 16 An additional difficulty is the "background noise" caused by day-today fluctuations in symptom severity and blood pressure (BP) readings in patients with autonomic failure. This could be, at least partially, overcome with the use of ambulatory 24-hour BP monitoring. 17, 18 Clinical trials for nOH were designed for relatively short periods of time (typically <4 weeks), and therefore significant clinical milestones, such as hospital admissions or mortality, were not used as endpoints. Patient-reported outcomes have limitations in subjects with nOH; reliance on symptoms alone may not always be an accurate indicator given that symptoms of nOH can be nonspecific, including fatigue and difficultly concentrating, and may occasionally mimic the levodopa off state in PD patients. Also, patients with PD can have difficultly distinguishing nOH-related lightheadedness from other causes of lightheadedness. 19 Furthermore, severity of nOH in PD and other synucleinopathies can be associated with disease progression; failure to demonstrate long-term improvement could conceivably be attributed to worsening of neurodegeneration rather than failure of the active agent.
Despite these challenges, there have been several accomplishments in the last years, including initiation and completion of large clinical trials, and the approval of new medications.
CARDIOVASCULAR AUTONOMIC DYSFUNCTION
Cardiovascular autonomic dysfunction occurs in virtually all patients with synucleinopathies, but only a minority of them are symptomatic. 20, 21 Symptoms of cardiovascular autonomic dysfunction are attributed to tissue hypoperfusion as a result of OH, defined as a sustained fall in BP of 20 mm Hg systolic or 10 mm Hg diastolic when moving from supine to standing. OH is a clinical sign, and it can be symptomatic or asymptomatic. Lightheadedness, blurry vision, and feeling faint are easily recognized as caused by OH; other less-specific symptoms include tiredness, cognitive impairment, dyspnea, neck and shoulder discomfort ("coat hanger pain"), or angina. Together with nOH, many patients with synucleinopathies have neurogenic hypertension in the supine position (nSH). nOH results in acute morbidity like syncope and falls whereas nSH causes end-target organ damage over time. Management of symptomatic nOH and nSH can be challenging as treating one usually aggravates the other.
Pathophysiology
Normally, unloading of the baroreceptors by standing up triggers norepinephrine release from sympathetic postganglionic nerves causing vasoconstriction, which maintains BP in the standing position. This compensatory vasoconstriction is absent or attenuated in patients with synucleinopathies resulting in nOH. The site of the "autonomic lesion" in the baroreflex pathways responsible for cardiovascular autonomic dysfunction is different in patients with LB disorders versus patients with MSA. In patients with LB disorders, cardiovascular dysautonomia is predominantly attributed to degeneration of postganglionic sympathetic neurons. There is robust imaging and neuropathological data showing that postganglionic peripheral sympathetic neurons innervating the myocardium are functionally affected because of aSyn deposits and fiber loss. 20, 21 Sympathetic fibers innervating blood vessels are also affected. This results in impaired norepinephrine release and defective vasoconstriction upon standing causing the BP to fall (i.e., nOH). 16, 20 Plasma norepinephrine, a marker of sympathetic neuronal integrity, is lower in patients with PD and nOH than in those without nOH. 22 In patients with MSA, cardiovascular autonomic dysfunction is caused by degeneration of CNS neurons involved in baroreflex control, whereas only a minority (< 30%) of patients has degeneration of postganglionic sympathetic nerves. [23] [24] [25] [26] [27] Norepinephrine release from peripheral sympathetic terminals is also blunted, but the nerves themselves are mostly spared. 21 Plasma norepinephrine levels are mostly normal in patients with MSA, 28 reflecting intact sympathetic neurons. These differences between LB disorders and MSA are relevant to determine the response to pharmacological treatment.
Epidemiology
In cross-sectional studies, between 30% and 50% of patients with PD have OH, but less than one third of those patients are symptomatic, that is, only 16% of patients with PD have symptomatic OH. 16, [29] [30] [31] Prevalence of OH in PD increases with age and disease duration. 29 In DLB, prevalence of OH is higher (50%-60%). 31, 32 In patients with MSA, the diagnostic criteria for nOH are a fall of 30 mm Hg in systolic or 15 mm Hg in diastolic BP. 33 Even according to these more stringent criteria, 70% to 80% of patients with MSA have nOH.
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Treatment of nOH
The goal of nOH treatment in patients with synucleinopathies is not to normalize standing BP, but to reduce symptom burden, improve quality of life, and reduce morbidity and mortality associated with nOH. 35 Consensus guidelines for the treatment of nOH are available. 36, 37 The steps of nOH management include: (1) correcting aggravating factors; (2) implementing nonpharmacological measures; and (3) drug therapies. When OH is asymptomatic, treatment may not be required or may be limited to nonpharmacological measures. When nOH is symptomatic (i.e., causing symptoms of organ hypoperfusion such as dizziness, lightheadedness, blurry vision or feeling about to faint), pharmacological treatment is usually required (Fig. 1) .
Correction of Aggravating Factors
Drugs that reduce intravascular volume (diuretics), induce vasodilatation (sildenafil, nitrates), or block norepinephrine release/activity at the neurovascular junction (a-blockers, centrally acting a 2 -agonists, and tricyclic antidepressants) worsen nOH and symptoms. L-dopa and dopamine agonists may also lower BP, and a dose adjustment may be considered based on an individual risk-benefit assessment. [38] [39] [40] [41] Anemia should be investigated and treated. 42 Erythropoietin (25-50 U/kg, subcutaneous, 3 times a week) in conjunction with iron supplements may be beneficial in patients with nOH and anemia. 43 
Nonpharmacological Treatment and Patient Education
Patients should be aware of the diuretic effects of caffeine and alcohol and avoid sugary beverages (e.g., bottled juices, sodas) because of the hypotensive effects of high-glycemic index carbohydrates. 44 Fluid intake should be 2.0 to 2.5 L/day. Patients should be encouraged to increase salt intake by adding 1 to 2 teaspoon of FIG. 1. Algorithm for the management of nOH in patients with synucleinopathies. A step-wise management of nOH includes: (1) correcting aggravating factors; (2) implementing nonpharmacological measures; and (3) drug therapies. When nOH is asymptomatic, treatment may not be required or may be limited to nonpharmacological measures. When nOH is symptomatic (i.e., causing symptoms of organ hypoperfusion such as dizziness, lightheadedness, and blurry vision or feeling about to faint), pharmacological treatment is usually required. *Droxidopa appears to be particularly effective in patients with low baseline plasma norepinephrine levels (usually patients with LB disorders). 64 **Atomoxetine appears to be particularly effective in patients with high baseline plasma norepinephrine levels (usually patients with multiple system atrophy).
63 # Caution is advised when combining droxidopa, with norepinephrine (NE) transporter (NET) inhibitors (e.g., atomoxetine), because this combination has not been systematically studied and there is a possibility of increasing the risk of arrhythmias and other adverse events. Ach, acetylcholine; AChoE, acetylcholine esterase. [Color figure can be viewed at wileyonlinelibrary.com] salt to a healthy diet. Other patients prefer using 0.5-to 1.0-g salt tablets, although they can cause abdominal discomfort. In patients with nOH, drinking 0.5 L of water produces a marked increase in BP. 45 This can be used as a rescue measure given that the pressor effect is quick (peaks in around 30 minutes), although short-lived.
Symptomatic nOH can quickly lead to a reluctance to stand up and avoidance of physical activity. In turn, physical immobility worsens OH, leading to a "vicious cycle" of deconditioning. 46 Physical exercise is therefore a key component of the therapeutic regimen, but because physical activity in the standing position can worsen hypotension in patients with autonomic failure, [47] [48] [49] [50] exercise should be performed in the recumbent or sitting position using a recumbent stationary bicycle or rowing machine. The exception is exercise in a pool because the hydrostatic pressure of water allows upright exercise without hypotension. 51 Patients should be taught specific physical countermaneuvers. 52 Eating results in blood pooling within the splanchnic circulation, and patients can become severely hypotensive within 2 hours of eating (i.e., postprandial hypotension), particularly after carbohydrate-rich meals. [53] [54] [55] [56] Eating smaller, more frequent meals and reducing carbohydrates can improve postprandial hypotension. Alcohol is also a vasodilator and should be reserved for the evening, before going to bed.
Patients should be instructed to change positions gradually and briefly sit before standing. Straining and Valsalva-like maneuvers during bowel movements are a common cause of syncope. 57 If this is the case, constipation must be treated aggressively. 58 High-waist compression stockings producing at least 15 to 20 mmHg of pressure can increase BP by augmenting venous return. 59 Patients with movement disorders struggle to put the stockings on, which limits their usefulness in everyday life. Elastic abdominal binders are a good alternative. 60, 61 A recently developed abdominal binder that inflates automatically only on standing had promising results in patients with nOH. 62 
Pharmacological Management
Even when nonpharmacological methods are performed properly, many patients still require pharmacological treatment to improve symptomatic nOH (Table 1 ). Figure 2 shows the sites of action and mechanism of therapeutic agents currently used in the treatment of nOH. Two complementary strategies are commonly used: (1) expanding intravascular volume with fludrocortisone and (2) increasing peripheral vascular resistance with midodrine, droxidopa, or norepinephrine transporter (NET) inhibitors. Selection of one or the others or both depends on the specific 
features and needs of each patient as well as the degree of peripheral sympathetic denervation. That peripheral sympathetic neurons are affected in LB disorders, but spared in MSA, is an important difference when planning therapeutic strategies for nOH. In healthy subjects, NET inhibitors have little effect on BP. This is because the peripheral effects of NET inhibitors on the sympathetic neurovascular junction enhancing noradrenergic vasoconstriction are counteracted by the increase in central nervous system (CNS) norepinephrine stimulating central a 2 -receptors, thus reducing central sympathetic outflow. In patients with MSA, however, only the peripheral vasoconstriction is apparent. Preliminary studies show that atomoxetine, a short-acting NET inhibitor, increases BP in patients with nOH according to their supine plasma norepinephrine levels. The higher the norepinephrine levels the greater the pressor effect and symptomatic improvement after atomoxetine. 63 Conversely, lower supine plasma norepinephrine levels appear to predict a greater symptomatic and pressor response to droxidopa, an oral norepinephrine synthetic precursor. 64 These responses can be explained by denervation supersensitivity of adrenergic receptors. 65 Thus, patients with low plasma norepinephrine levels (usually LB disorders) may benefit more from droxidopa and midodrine, whereas patients with normal or high plasma norepinephrine levels (usually MSA) may potentially benefit more from NET inhibitors (Fig. 1 ). In patients with refractory nOH, NET inhibition could be theoretically combined with droxidopa or midodrine, with or without fludrocortisone or pyridostigmine. However, no safety data are available on the combined use of any of these agents and its use may result in severe hypertension and cardiac arrhythmias.
Fludrocortisone. Fludrocortisone (9a-fluorocortisol) is a synthetic mineralocorticoid that increases BP by at least two mechanisms: It increases renal sodium and water reabsorption, thus expanding intravascular volume, and also enhances pressor responsiveness to endogenous catecholamine and pressor drugs. 66 Fludrocortisone exacerbates SH and end-organ target damage (left ventricular hypertrophy and renal failure) and may increase the risk of all-cause hospitalization. 67 Additional, frequent adverse events include hypokalemia and ankle edema. 66, 68 To reduce the risk of hypokalemia, patients taking fludrocortisone should be instructed to eat potassium-rich foods or potassium chloride supplements (10-20 mEq/day). Fludrocortisone dosage should not exceed 0.2 mg/day. Higher dosages are rarely more effective, but intensify adverse events. Appreciable clinical improvements usually require 7 days of treatment. Fludrocortisone is available in most countries, although it is not specifically approved for the treatment of nOH in any countries.
Pressor agents. Midodrine. Midodrine is an oral a 1 -adrenoceptor agonist that induces vasoconstriction and increases BP. 15, [69] [70] [71] Midodrine is approved for the treatment of symptomatic OH in the United States, Europe, and Asia. Midodrine raises BP in the standing, sitting, and supine positions and its pressor effect is noticeable 30 to 45 minutes after consumption, reaching a maximum after 1 hour, and persists for a total of 2 to 3 hours. Treatment should begin with a 2.5-or 5-mg
Sites of action and mechanism of therapeutic agents used for the treatment of nOH. Pyridostigmine inhibits acetylcholine esterase (AChoE) in the sympathetic ganglion, thereby increasing the levels of acetylcholine (ACh) and enhancing sympathetic neurotransmission. Droxidopa is converted to norepinephrine (NE) through the action of the enzyme, AAAD, both in neuronal and extraneuronal tissues. Atomoxetine and similar medications block the NE transporter (NET), thereby increasing NE levels in the sympathetic terminal. Midodrine is a direct alpha-adrenergic agonist that activates the same receptor as NE. Finally, fludrocortisone is a synthetic mineralocorticoid that increases intravascular volume.
dose, which can then be increased up to 10 mg to be taken up to 3 times a day. nSH is common, hence patients should not take midodrine less than 3 to 4 hours before bedtime. Other adverse events owing to activation of a1-adrenergic receptors are piloerection ("goosebumps"), itching of the scalp, and urinary retention. Midodrine has no effect on heart rate because it does not activate b-adrenoreceptors and, given its poor diffusion across the blood-brain barrier, has no CNS adverse effects. 72 
Droxidopa.
Droxidopa (L-threo-3,4-dihydroxyphenyl-serine) is an oral synthetic amino acid that is converted to norepinephrine in the body. 13 Droxidopa is decarboxylated to norepinephrine by the enzyme, aromatic amino-acid decarboxylase (AAAD), the same enzyme the converts L-dopa to dopamine. Droxidopa was approved in Japan in 1989 for the treatment of nOH in PD, MSA, and familial amyloid polyneuropathy. In the United States, the U.S. Food and Drug Administration (FDA) approved droxidopa in 2014 for treatment of symptomatic nOH associated with PAF, PD, and MSA.
14,73-76 Droxidopa is not approved in Europe. Extensive clinical experience shows that droxidopa is safe and well tolerated. [77] [78] [79] [80] [81] [82] [83] [84] [85] Peak plasma concentrations of droxidopa are reached 3 hours after oral administration. The dosage used in clinical trials was 100 to 600 mg 3 times/day, although clinical experience indicates that the dosage should be tailored to each patient's needs considering the periods of time when he or she is going to be active or inactive. 13, 78, 83 Because the pressor effect of droxidopa varies among patients, a titration procedure supervised by a clinician is highly recommended. 16 Ambulatory 24-hour BP monitoring is useful to evaluate the BP profile before and after initiating treatment with droxidopa. 17 Inhibition of the AAAD with high doses of carbidopa can abolish the pressor effect of droxidopa by preventing its peripheral conversion to norepinephrine. This was shown in studies using a single 200-mg dose of carbidopa administered 30 minutes before droxidopa. 86 In clinical practice, the dose of carbidopa in patients treated with L-dopa is lower than 200 mg, thus carbidopa appears not to block the pressor effect of droxidopa significantly. 77 Further studies are warranted to determine whether droxidopa has beneficial effects on other motor and nonmotor symptoms that result from norepinephrine deficiency in patients with PD. 87 Norepinephrine Transporter Blockers. Atomoxetine and similar medications increase norepinephrine concentration in the sympathetic neurovascular junction by selectively blocking the NET. Atomoxetine (Strattera) is currently approved in the United States, Europe, and Asia for the treatment of attention deficit and hyperactivity disorder in children, adolescents, and adults. The rationale for using atomoxetine as an off-label medication for symptomatic nOH originates from three randomized, placebo-controlled, short-term trials, [88] [89] [90] all of which showed that atomoxetine significantly increased standing BP and reduced the burden of symptoms compared to placebo. Atomoxetine is a very safe medication; the most common adverse events are decreased appetite, dry mouth, insomnia, and nausea. 91 Severe hepatitis has been anecdotally reported. 92 An oligo-center double-blind, placebocontrolled crossover clinical trial to confirm the efficacy of atomoxetine for nOH is currently underway (NCT02796209). Because atomoxetine has a relatively short biological effect (4-5 hours), longer active NET blockers may be required. In this regard, an investigational long-acting NET blocker and serotonin reuptake inhibitor (TD-9855), previously studied in patients with fibromyalgia, is being currently assessed in a phase 2, multicenter, single-blind, placebo-controlled trial with an open-label extension phase (NCT02705755).
Pyridostigmine.
Pyridostigmine, a cholinesterase inhibitor, potentiates cholinergic neurotransmission in sympathetic and parasympathetic autonomic ganglia. Pyridostigmine is widely available in most countries. A double-blind study showed that pyridostigmine increases, on average, 4 mm Hg in standing systolic BP. 93 The combination of 5 mg of midodrine with 60 mg of pyridostigmine was more effective than pyridostigmine alone. Pyridostigmine appears to be less effective than midodrine to improve nOH-related symptoms. 94 Neurogenic Supine Hypertension nSH occurs in up to 50% of patients with PD and with MSA. 29, [95] [96] [97] In patients with MSA, residual sympathetic neurovascular tone may contribute to SH. In contrast, SH in patients with LB disorders has a mechanism other than increased sympathetic outflows, yet to be fully identified. 98, 99 Patients with nOH who also have nSH are less likely to develop symptomatic nOH after 3-minute standing 29 because their BP in the standing position is above the lower level of cerebral autoregulatory capacity. Cerebral vasomotor reactivity is preserved in patients with PD, which may contribute to lack of symptoms of cerebral hypoperfusion during hypotension. 100, 101 The goal of treatment of nSH in patients with synucleinopathies is to minimize the risk of end-target organ damage without worsening hypotension, thus reducing morbidity and mortality. Achieving this goal is challenging. During daytime, avoiding the supine position is the best treatment. If needing to rest, patients should sit in a reclining chair with feet on the floor. At night, tilting the bed to achieve a 30-or a 45-degree angle (so that the patient sleeps with his or
her head and torso above his or her legs) lowers BP. 102 This is best accomplished with an electric bed or mattress, rather than just using extra pillows or a wedge. In addition, lowering BP during the night reduces the exaggerated nocturia and natriuresis of these patients, therefore reducing overnight volume depletion, and improving OH in the morning. Use of midodrine, droxidopa, or other pressor agents should be avoided before bedtime. Other nonpharmacological measures such as eating carbohydrates snacks or have an alcoholic drink before bedtime also contribute to decrease nocturnal nSH. The application of local abdominal heat to reduce supine BP is being currently studied in a clinical trial (NCT02417415).
Antihypertensive drugs may be necessary in patients with severe nocturnal nSH that persists after nonpharmacological measures, particularly if they already have end-organ target damage (Table 2) . 35, 103, 104 When antihypertensive drugs are prescribed, patients should be warned about the increased risk of hypotension and falls when they get up at night to urinate. To avoid this, the use of a urinal or bedside commode should be encouraged.
SWALLOWING AND GASTROINTESTINAL DYSFUNCTION
In patients with synucleinopathies, gastrointestinal function is affected at all levels, from chewing to defecation. 105, 106 Dysphagia in patients with PD and DLB is usually mild and occurs late in the disease course, whereas in patients with MSA it can be early and severe. 107 Aspiration pneumonia, the most feared complication of dysphagia, is a common cause of death in patients with synucleinopathies. 108 Upper gastrointestinal symptoms (attributed to esophageal dysmotility and gastroparesis) and lower gastrointestinal symptoms, such as constipation, are virtually universal in patients with PD, DLB, and MSA and contribute to decreased quality of life. 109 
Pathophysiology
Swallowing is a complex stereotyped motor activity. Like gait, swallowing is controlled by a central pattern generator in the medulla, which receives cortical and subcortical projections and is modulated by the pedunculopontine tegmental nuclei. 110 Sensory input from the oropharynx initiates and controls swallowing through trigeminal, glossopharyngeal, and vagal afferents. The swallowing interneurons include neurons in the nucleus tractus solitarii (NTS) that receive sensory afferents from oropharynx and other neurons of the reticular formation. Effector neurons are in the hypoglossal (XII) nuclei in the medulla, which innervates extrinsic and intrinsic muscles of the tongue, the nucleus ambiguous, which innervates all striated muscles of the pharynx and larynx through vagal fibers, and the dorsal nucleus of the vagus, which provides efferent parasympathetic preganglionic fibers to the esophagus and the rest of the gastrointestinal tract, up to the splenic flexure of the colon and abdominal organs. Vagal efferents connect with neurons of the enteric nervous system (ENS).
In patients with synucleinopathies, involvement of medullary neurons (NTS, mesolimbic cholinergic, and pre-B€ otzinger complex) results in oropharyngeal, vocal cord, and esophageal abnormalities. 107, 111, 112 In patients with PD, aSyn aggregates in the glossopharyngeal nerve, the pharyngeal sensory branch of the vagus nerve, and the internal superior laryngeal, a sensory branch of the vagus nerve innervating the laryngopharynx, correlate with the severity of dysphagia. 113 Involvement of pharyngeal sensory nerves causes decreased pharyngeal sensation, contributing to dysphagia and aspiration.
Esophageal abnormalities in patients with PD include incomplete relaxation of the upper and lower esophageal sphincters, diffuse esophageal spasms, and reduced esophageal peristalsis. 114, 115 Stool transit time is prolonged in patients with LB disorders because colonic motility is reduced because of abnormal intrinsic (ENS) and extrinsic (vagal) innervation. Preliminary evidence also shows early enteric sympathetic denervation. 116 Autopsy findings in patients with PD and DLB show aSyn pathology in enteric neurons along the entire gastrointestinal tract, from the esophagus to the colon, particularly in neurons of Auerbach plexus in the lower esophagus. 117, 118 Some symptoms, such as delayed gastric emptying, can be aggravated by the effect of L-dopa on dopaminergic enteric receptors that slow motility. 119 In patients with MSA, neurodegeneration of brainstem nuclei (including the dorsal motor nucleus of the Clonidine carries a risk of a severe morning hypotension as well as rebound hypertension.
vagus), the intermediolateral cell column in the thoracic and lumbar spinal cord, account for the gastrointestinal symptoms; aSyn accumulation spares the autonomic nerves in the abdominopelvic organs and the ENS.
8,120
Epidemiology Dysphagia in patients with LB disorders is related to the severity of the disease. It is a complaint of at least 35% of patients with PD and 73% of patients with MSA. [121] [122] [123] Videofluoroscopy reveals abnormal swallowing in the majority of patients with PD and MSA. Reduced efficiency and frequency of swallowing result in excessive saliva (sialorrhea or drooling) in 50% to 60% patients with PD and MSA, particularly in advanced stages. 106, 124 Virtually all patients with LB disorders and MSA have gastroparesis (i.e., delayed gastric emptying), causing them to suffer nausea, early satiety, gastric retention, and abdominal distension. [125] [126] [127] [128] Constipation is the single-most-common autonomic and gastrointestinal symptom, reported by up to 90% of patients with PD and 80% of patients with MSA. 109, [129] [130] [131] [132] Constipation is now recognized as a reliable autonomic disturbance in the premotor phase of PD and DLB and can also occur in the premotor stages of MSA 11, [133] [134] [135] Disorders associated with constipation in PD and MSA include colonic volvulus, intestinal pseudo-obstruction, megacolon, fecal impaction, or overflow diarrhea.
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Treatment of Dysphagia and Drooling
Patients with mild-to-moderate dysphagia may benefit from postural changes, behavioral changes (e.g., reduced meal volumes and eating slowing), and modified meal consistencies (e.g., liquid thickeners). 107 Expiratory muscle strength training and video-assisted swallowing therapy may be effective treatments for dysphagia in patients with PD and may also be helpful in patients with MSA. 138 Botulinum toxin injections in the distal esophagus have shown some promise to improve esophageal dysphagia in patients with PD. 139 Neuromuscular electrical stimulation of the suprahyoid muscles in patients with PD showed no benefits compared to behavioral/postural modifications. 140 The role of dopaminergic drugs and DBS surgery is controversial. [141] [142] [143] Some patients with MSA underwent tracheostomy and laryngeal closure surgery for the treatment of dysphagia with conflicting outcomes. 144, 145 If dysphagia is severe, avoidance of the oral route with a gastrostomy tube placement to ensure adequate nutrition/hydration and reduce the risk of aspiration should be discussed with the patient.
Patients with sialorrhea may benefit from several treatment approaches. Oral glycopyrrolate (1 mg twice-daily) is efficacious for the very short-term treatment of sialorrhea in PD. 12, 146 Side effects include dry mouth, urinary retention, constipation, and blurry vision. Local administration of anticholinergics (e.g., sublingual atropine drops 147 or ipratropium spray 148 ) could be considered as alternative with no systemic adverse events, although the evidence is insufficient. 12 Botulinum toxin injections into the salivary glands are efficacious to reduce sialorrhea in patients with PD, 12 although repeat injections are typically required every 3 to 6 months. 149 Behavioral modification (e.g., instructing patients to carefully swallow their saliva at specific times) 150 and radiotherapy 151 were effective for patients with PD and MSA in small studies.
Treatment of Gastroparesis
The goals of gastroparesis treatment are alleviation of symptom burden, correction of malnutrition, and resumption of oral intake, when possible. 152 Dietary modifications, including a low-fat diet with small frequent meals and liquid nutrients, can help with gastroparesis. The modulation of gastric motility is complex and involves cholinergic, dopaminergic, serotoninergic, and motilin receptors (Fig. 3) . Available pharmacotherapy for gastroparesis includes dopamine blockers, cholinergic enhancers, serotonin agonists, and motilin receptor agonists, although none of these have been tested in controlled clinical trials in PD.
Dopamine Receptor Blockers
D 2 receptor blockers can have both central and peripheral activity. Central and peripheral dopamine blockers include metoclopramide, itopride, and levosulpiride (the latter two not available in the United States). Because of their CNS adverse events, including aggravation of parkinsonism and dyskinesias, and because they can worsen hypotension, 153 central dopamine receptor blockers are contraindicated in patients with parkinsonism or with autonomic failure. 154 Moreover, metoclopramide can prolong the QT interval and increase risk of arrhythmias. Domperidone, a dopamine blocker that does not cross the CNS, is not approved in the United States because of its potential to increase the QT interval. It is available in Europe and Canada. The International Parkinson and Movement Disorder Society (MDS) Evidence-Based Medicine Review on NonMotor Treatments for PD considered domperidone as likely efficacious for the treatment of gastroparesis. 146, 155 Interestingly, domperidone has been extensively used to blunt the potential hypotensive effects of L-dopa and dopaminergic agonists. 156 
Motilin Receptor Agonists
Motilin, a hormone secreted by gastric M cells, stimulates gastric motility through motilin receptors in the smooth muscle. Erythromycin, a widely available antibiotic, is a potent prokinetic that stimulates
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motilin receptors. 152 Although gastric emptying is increased with oral erythromycin, this improvement appears to be smaller than with intravenous erythromycin. 157 The dosage of intravenous erythromycin is 3 mg/kg every 8 hours. Oral erythromycin can be given 10 mg 3 times/day. Potential adverse events include abdominal pain and antibiotic resistance. Adverse events of erythromycin include gastrointestinal toxicity, ototoxicity, antibiotic resistance, and QT prolongation. Erythromycin is a strong cytochrome P450 inhibitor, which should be taken into consideration to avoid pharmacological interactions. Azithromycin has a longer half-life, fewer gastrointestinal adverse effects, and less drug interactions than, and similar efficacy to, erythromycin, although it may also cause QT prolongation and arrhythmias. 158 Synthetic motilin receptor agonists without antibiotic properties, such as camicinal, are undergoing clinical trials. 159 
Serotonin Agonists
Two nonselective serotonin 5-HT 4 agonists (cisapride and tegaserod) were developed to increase gastric motility, but were withdrawn in the United States and Asia and were severely restricted in Europe because of QT interval prolongation and heart ischemia. Highly selective serotonin agonists (mosapride or prucalopride) for the treatment of constipation, although not approved in the United States, are available in other world regions such as Europe, Asia, and South America. Because they are highly selective and have little effect on cardiac potassium channels, no cardiovascular adverse events have been reported, although their usefulness for gastroparesis has not been systematically investigated.
Other Treatments
Muscarinic agonists (e.g., bethanechol) and acetylcholinesterase inhibitors (e.g., pyridostigmine) can increase lower esophageal sphincter pressure and trigger fudoantral contractions and may be used for gastroparesis. 160 Nizatidine, an H 2 -receptor antagonist with anticholinesterase activity, stimulates gastric emptying. 161 The benefit of endoscopic pyloric botulinum toxin injections has been documented in small   FIG. 3 . Sites of action and mechanisms of therapeutic agents used for the treatment of gastroparesis. Several receptors (dopaminergic, cholinergic muscarinic, cholinergic nicotinic, and serotoninergic, among others) are involved in the regulation of gastric motility. Eventually, all modulate acetylcholine release in the enterocyte, which induces gastric motility. Agents used to increase motility include dopamine D 2 receptor blockers (e.g., domperidone and others), serotonin 5-HT 4 receptor agonists (e.g., cisapride and others), acetcylcholinesterase inhibitors (e.g., pyridostigmine), and muscarinic agonists (e.g., betanechol). Conversely, 5-HT 3 antagonists (e.g., alosetron, ondansetron) reduce gastric motility and are used for diarrhea or vomiting.
case series of PD patients. 162 ,163 STN-DBS can improve gastric emptying in PD. 164 Gastric electrical stimulation could potentially be considered for severe and refractory gastroparesis. 165 Ghrelin receptor agonists are being tested in clinical trials. 159 
Treatment of Constipation
Guidelines for the management of constipation in patients with synucleinopathies are lacking. 166, 167 Constipation management includes nonpharmacological approaches, removal of aggravating factors (e.g., opioids), fiber supplements, stool softeners, and pharmacotherapy (Fig. 4) . Enemas and manual disimpactions may be required in severely affected patients.
Nonpharmacological Measures
A controlled clinical trial showed that fermented milk products with probiotics (e.g., kefir) improved constipation in patients with PD. 168 Additional dietary modifications usually recommended, although not studied in clinical trials, include eating at the same time of the day, increasing high-fiber fruits and vegetables, extra virgin olive oil, wholegrain breads, and wholegrain cereals in daily meals, as well as hydration (2.0-2.5 L per day) and physical activity.
Bulk Laxatives and Osmotic Laxatives
Oral bulking agents (fiber supplements such as psyllium or methylcellulose) can be added to the dietary and nonpharmacological modifications. 169 Of these, psyllium is the only one studied, showing efficacy to increase bowel movement frequency in a randomized trial of PD patients. 170 Adequate hydration is required with bulk formers; otherwise constipation may worsen. Osmotic laxatives (polyethylene glycol, magnesium, docusate sodium, and lactulose) act by osmotically drawing water into the gastrointestinal lumen and softening the fecal mass. Some of them also have rectal administration. Polyethylene glycol (macroglol) showed efficacy to increase bowel movement frequency in a controlled trial of patients with PD and was considered likely efficacious in the MDS Evidence-Based Review on Non-Motor Treatments for PD. 12, 171 Adverse events are usually limited to mild gas/bloating, mild nausea, and, occasionally, diarrhea.
Stimulant Laxatives
Stimulant laxatives (bisacodyl, sodium picosulfate, and senna) activate the gastrointestinal mucosa by chemical irritation-inducing fluid and sodium chloride secretion and colonic motility. Adverse events include salt overload, hypokalemia, and proteinlosing enteropathy. Although initial observations suggested that long-term use could induce ENS damage, biological evidence and guidelines indicate that stimulant laxatives are safe and effective for chronic constipation. 169, 172 Chloride Channel Activators
Luminal chloride channel activators are approved for the treatment of chronic constipation in the United FIG. 5. Luminal chloride channel activators for the treatment of chronic constipation in patients with synucleinopathies. Lubiprostone is a locally acting chloride type 2 channel activator. Linaclotide is an agonist of the guanylate cyclase 2C receptor. Activation of guanylate receptors leads to a metabolic cascade that increases the secretion of chloride and HCO 3 through the CFTR receptor. Linaclotide also increases smooth muscle contraction, promoting bowel movements, and reduces activation of colonic afferent sensory neurons, theoretically reducing gastrointestinal pain. Plecanatide, another oral guanylate cyclase-C receptor agonist, also showed efficacy in placebocontrolled, randomized trials to increase spontaneous bowel movements.
FIG. 4.
Algorithm for the management of constipation in patients with synucleinopathies. Management includes nonpharmacological approaches, removal of aggravating factors (e.g., opioids), fiber supplements, stool softeners, and pharmacotherapy with laxatives. The asterisk (*) denotes nonpharmacological and pharmacological agents tested in clinical trials of patients with PD. Enemas and manual disimpactions may be required in severely affected patients (not shown in algorithm). [Color figure can be viewed at wileyonlinelibrary.com]
States, Europe, and Asia ( Figure 5 ). Lubiprostone is a locally acting chloride type 2 channel activator. In a randomized, placebo-controlled, clinical trial of lubiprostone in 52 patients with PD, lubiprostone 24 lg twicedaily significantly reduced the burden of constipation and increased the number of daily bowel movements compared to placebo. 173 Adverse events were mild, most commonly intermittent diarrhea. Other reported adverse events in controlled trials include nausea and headache. Linaclotide is an agonist of the guanylate cyclase 2C receptor. Activation of guanylate receptors leads to a metabolic cascade that increases the secretion of chloride and HCO 3 through the CFTR receptor (the one affected in cystic fibrosis). In addition, linaclotide also increases smooth muscle contraction, promoting bowel movements, and reduces activation of colonic afferent sensory neurons, theoretically reducing gastrointestinal pain. Although it has not been specifically studied in patients with synucleinopathies, randomized, placebo-controlled trials performed in subjects with chronic constipation showed that 290 or 145 lg of linaclotide once-daily 30 minutes before breakfast significantly increased daily spontaneous bowel movements. 174 Potential adverse events include diarrhea, abdominal bloating, and flatulence. Plecanatide, another oral guanylate cyclase-C receptor agonist, also showed efficacy in placebo-controlled, randomized trials to increase spontaneous bowel movements. 175, 176 It was FDA approved in 2017 for the treatment of chronic idiopathic constipation and may prove useful in patients with synucleinopathies.
Serotonin Agonists and Others
Cisapride and tegaserod, both 5-HT 4 receptor agonists, were effective to improve constipation in patients with PD, [177] [178] [179] [180] but were withdrawn in most countries because of severe adverse events. Prucalopride and mosapride are high-affinity 5-HT 4 receptor agonists with partial 4-HT 3 -antagonist activity (available in several countries in Europe, Asia, and South America, but not in the United States). Mosapride specifically ameliorated constipation in an open-label study including 14 patients with PD. 181 New compounds such as elobixibat, an ileal bile acid transporter inhibitor, 182 and relamorelin, a centrally acting ghrelin receptor agonist, are being tested in clinical trials. 159, 183 In a single-center randomized, double-blind, placebo-controlled trial, relamorelin administered subcutaneously once-or twicedaily, relieved constipation and accelerated colonic transit compared to placebo during a 14-day treatment period. 184 Further clinical trials are underway.
URINARY DYSFUNCTION
Urinary symptoms, related to neurogenic detrusor overactivity or underactivity, are very common in patients with synucleinopathies. 185 These include nocturia, frequency, urgency, and, in some patients, urinary retention. In patients with LB disorders, urinary dysfunction is mild or moderate and typically appears later, whereas in patients with MSA, urinary dysfunction is universal, severe, and one of the earliest presenting features. 11, 186 Indeed, male patients with premotor MSA frequently undergo surgery for suspected benign prostate hyperplasia without realizing that MSA is the actual cause of their urinary problems. In these cases, urological surgery outcomes are rarely favorable. Urinary dysfunction in LB disorders is probably a combination aSyn-mediated disruption of peripheral genitourinary autonomic pathways and basal ganglia dysfunction, whereas disruption of the Onuf nucleus is the main contributor to urinary dysfunction in patients with MSA.
118,187-189
Epidemiology
Urinary symptoms affect up to 80% of patients with LB disorders, mostly related to neurogenic detrusor overactivity. [188] [189] [190] Nocturia is the most commonly reported symptom (up to 80%) followed by frequency (up to 70%), urgency (up to 70%), and urge incontinence (up to 40%), both in women and men. 190 Hesitancy affects up to 40% of PD patients. 188 In patients with MSA, voiding difficulty is the most frequently reported urinary symptom (80%) followed by nocturia (74%), urgency (63%), incontinence FIG. 6 . Sites of action and mechanisms of therapeutic agents used for the treatment of neurogenic overactive bladder. Cholinergic pelvic nerves release acetylcholine (ACh), which, through activation of muscarinic M3 receptors, induce contraction of the detrusor muscle and emptying of the bladder. Antimuscarinic agents (e.g., solifenacin) block the muscarinic receptor and reduce detrusor muscle contractions. Hypogastric adrenergic nerves release norepinephrine (NE), which causes urinary retention by activating b 3 -adrenergic receptors in the detrusor muscle and alpha-adrenergic receptors in the internal sphincter of the urethra. Mirabegron, a b 3 -adrenergic receptor agonist, reduces bladder contractions in patients with neurogenic detrusor overactivity. Of note, the classical nomenclature of the sacral autonomic outflow has been recently challenged.
, diurnal frequency (45%), nocturnal enuresis (19%), and urinary retention (8%). 191 Around 40% of patients with MSA have neurogenic detrusor overactivity (i.e., overactive bladder) during the filling phase, and this may be accompanied by uninhibited external sphincter relaxation (i.e., detrusor-sphincterdyssynergia), which worsens the severity of urge incontinence. 192, 193 Detrusor underactivity resulting in increased postvoid residual volume is infrequent (10%) in LB disorders and urinary catheterization is seldom required. 190 In patients with MSA, however, detrusor underactivity occurs in approximately 70%, resulting in a large amount of bladder postvoid residual volume. 192 Poor management of bladder dysfunction can increase the risk of urosepsis and death. 194 Figure 6 summarizes the autonomic control of the bladder with its pharmacological targets. Management with mirabegron or antimuscarinic agents and behavioral treatment (e.g., prompted/timed bladder emptying) is the treatment of choice of neurogenic detrusor overactivity, although only one controlled clinical trial (with solifenacin) has been performed in this population so far. 195 An uncontrolled study showed that exercise-based, biofeedback-assisted behavioral training was effective to reduce the frequency or urination and improve quality of life in patients with PD with urinary incontinence. 
Treatment of Neurogenic Detrusor Overactivity
Antimuscarinic Agents
Antimuscarinic drugs improve symptoms of detrusor overactivity by reducing cholinergic output to the bladder and thus relaxing the detrusor muscle and reducing the urge to urinate.
Antimuscarinic agents can worsen the postvoid residual volume and cause urinary retention, dry mouth, dry eyes, gastroparesis, and constipation. There are several antimuscarinic agents, the majority of which are available in most world regions: They share mechanism of action, but differ in selectivity of M 3 receptors and CNS permeability (Table 3) . Centrally acting antimuscarinic (e.g., atropine or scopolamine) or predominantly peripheral with CNS penetrance (oxybutynin, fesoterodine) can cause/aggravate cognitive impairment and should be avoided. Peripherally acting antimuscarinics with low CNS penetrance (e.g., trospium, darifernacine) are preferable. Only solifenacin (5-10 mg daily) has been specifically studied in a randomized, placebo-controlled trial of patients with PD showing a significant reduction in urinary frequency compared to placebo. 195 
Other Treatments
Alpha-adrenergic blockers (tamsulosin, silodosin) should be used very cautiously, or not at all, in patients with autonomic dysfunction because they can aggravate 
OH and increase the risk of falls and syncope. Openlabel studies showed that intramural botulinum toxin injections in the bladder can improve refractory neurogenic detrusor overactivity in patients with PD and MSA; potential adverse events include urinary retention. [198] [199] [200] Nocturnal natriuresis in patients with supine hypertension and nOH should be distinguished from neurogenic detrusor overactivity. Treatment with intranasal desmopressin can reduce nocturia in PD, 201 but because of its high risk of adverse events (hyponatremia, cognitive impairment), it is not routinely recommended. STN-DBS appears to reduce urinary frequency and incontinence in patients with PD. 202 Globus pallidus DBS may yield similar results, 203 although controlled studies are warranted. Preliminary studies with implantable sacral nerve stimulation, 204, 205 transcutaneous tibial nerve stimulation, 206, 207 or transcranial magnetic stimulation 208 in PD or MSA showed promising results to ameliorate neurogenic overactive bladder, although controlled studies are required.
Treatment of Detrusor Underactivity
Incomplete bladder emptying as a consequence of detrusor underactivity is common in MSA and seldom reported in patients with PD, DLB, or PAF.
Estimation of the postvoid residual (PVR) bladder volume is a simple and useful test in patients with MSA; even though their urinary complaints may be limited to urinary urgency or frequency, patients are usually unaware that their bladders do not empty completely. PVR can be measured by ultrasound echography or transurethral catheterization. If the patient has a PVR >100 mL, clean intermittent self-catheterization must be recommended. Either the patient or the caregiver can usually perform this after education is provided. In patients with advanced disease and severe neurological disability, a permanent indwelling catheter, usually suprapubic, may be required. Antimuscarinic or b 3 -adrenergic treatment to reduce bladder overactivity should be added regardless of the PVR. The caveats are the same as with the treatment of overactive bladder. Replaceable remote-controlled intraurethral prosthesis for women with underactive bladder have been recently approved by the FDA 209 ; these do not require surgery, increase quality of life, and reduce the risk of urinary complications, although the experience in patients with MSA is still limited (Fig. 7) .
SEXUAL DYSFUNCTION
Sexual dysfunction, including erectile dysfunction, ejaculation problems, and difficulties achieving orgasm, is an extremely common problem in patients with synucleinopathies, typically appearing early in the course of the disease. Erectile dysfunction in LB and MSA may reflect dopamine deficiency in addition to disruption of autonomic pathways.
Epidemiology
Up to 79% of men with PD acknowledge erectile dysfunction, ejaculation problems, and difficulties achieving orgasm. This increases up to 100% in patients with MSA. 210 The severity of sexual problems increases with disease duration. 211 Erectile dysfunction can appear years before the diagnosis of PD or MSA, adding sexual dysfunction to the constellation of premotor autonomic biomakers of synucleinopathies. 11, 212 Up to 75% of women with PD and MSA report sexual problems such as vaginal dryness, decreased libido, and difficulties reaching orgasm.
Treatment of Erectile Dysfunction
Psychogenic causes (anxiety, depression, and stress) and excessive use of alcohol and tobacco can contribute to erectile dysfunction. 213 Several medications can induce erectile dysfunction and decreased libido. These include hydrochlorothiazide and b-blockers (which can also induce OH). Selective serotonin reuptake inhibitors and 5a-reductase inhibitors (finasteride) can also contribute to erectile dysfunction. Prostate cancer treatments (radical prostatectomy, radiotherapy, luteinizing FIG. 7 . Algorithm for the management of underactive bladder in patients with synucleinopathies. Incomplete bladder emptying as a consequence of detrusor underactivity is common in MSA, but seldom reported in patients with other synucleinopathies. Estimation of the PVR bladder volume is a simple and useful test in patients with MSA; even though their urinary complaints may be limited to urinary urgency or frequency, patients are usually unaware that their bladders do not empty completely. PVR can be measured by ultrasound echography or transurethral catheterization. If the patient has a PVR >100 mL, clean intermittent self-catheterization must be recommended. Either the patient or the caregiver can usually perform this after education is provided. In patients with advanced disease and severe neurological disability, a permanent indwelling catheter, usually suprapubic, may be required. Antimuscarinic or b 3 -adrenergic treatment to reduce bladder overactivity should be added regardless of the PVR. Therapeutic options for erectile dysfunction include phosphodiesterase type 5 (PDE-5) inhibitors, intracavernosal injection therapy, vacuum pump devices, intraurethral prostaglandin suppositories, and surgical placement of penile prostheses.
PDE-5 inhibitors enhance blood flow in the corpora cavernosa, promoting and maintaining the erection of the penis. PDE-5 inhibitors have been the mainstay of erectile dysfunction treatment since the release of sildenafil in 1998, with the subsequent development of other similar agents, which differ in half-life. 214 Sildenafil is the shorter acting (half-life of 4 hours) and should be taken 30 to 60 minutes before intercourse. Sildenafil improved erectile dysfunction in small open-label studies of patients with PD 215, 216 and in a small randomized, placebo-controlled trial of patients with PD and MSA. 217 Although PDE-5 inhibitors are usually safe and effective in patients with synucleinopathies, their main limiting factor is that they induce systemic vasodilation that can cause dramatic reductions in BP, with symptomatic OH and syncope. Thus, it is important for clinicians recommending PDE-5 inhibitors to patients with autonomic synucleinopathies to always prescribe the shorter acting one (i.e., sildenafil) and to advise against being standing for several hours after taking a dose. In addition, clinicians should make the patient aware of the action of the drugs, with the following caveats: (1) they do not result in an immediate erection; (2) they do not cause an erection without sexual stimulation; and (3) they may not work every time.
Vacuum pump devices are clear plastic chambers placed over the penis, tightened against the lower abdomen with a mechanism to create a vacuum inside the chamber. This results in increased blood flow into the penis. If an adequate erection occurs inside the chamber, the patient slips a small constriction band off the end of the vacuum pump device and onto the base of the penis. An erection beyond 30 minutes with this method is not recommended. These devices can result as a bit cumbersome, but are safe and tolerable, and patients with autonomic dysfunction can get used to them. 218 Implantable inflatable prostheses were introduced in 1973 and are still used today. 213 The use of direct injections of alprostadil, either intracavernosal or intraurethral, is another option. 219 A small needle is used to inject the medication into the lateral aspect of the penis through a small-gauge needle. Response is dose related and usually occurs within 10 to 15 minutes and does not require sexual stimulation. The intraurethral preparation (MUSE) consists of a small amount of drug inserted into the urethral meatus. Response is also dose related and onset similar to the cavernosal preparations. Adverse events include painful erection, erection lasting >6 hours, and testicular pain/ swelling. Apomorphine, a dopaminergic agonist used in subcutaneous injections in patients with PD and severe motor fluctuations, induces penile erection. 220 Sublingual apomorphine 2 or 3 mg to treat erectile dysfunction had promising results in clinical trials and is approved in some countries (e.g., France) for this indication; however, nausea, dizziness, and hypotension are relatively common adverse events.
221-223
Treatment of Female Sexual Dysfunction
Therapeutic options for female sexual dysfunction are limited and include vaginal lubrication, hormonal therapy, and psychotherapy. 224 
CONCLUSIONS
The role of ANS dysfunction in PD and other synucleinopathies has evolved from just an adverse event to playing a key role in the etiology, treatment, and biomarker of early diagnosis and disease progression. [225] [226] [227] Dysfunction of the ANS afflicts most patients with synucleinopathies, affecting quality of life and mortality. Successful treatment of autonomic dysfunction is possible and symptomatic treatments are available. Gastrointestinal dysfunction can lead to impaired drug pharmacodynamics, causing a worsening in motor function. OH can cause syncope, falls, and fractures. Urinary retention can cause sepsis and death. Thus, there should be a low threshold for ancillary testing to better detect and treat autonomic dysfunction in patients with synucleinopathies. Nonpharmacological treatments are useful and should be tried first. Pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries. Novel therapeutic approaches currently being tested in clinical trials will expand the therapeutic arsenal against autonomic dysfunction in forthcoming years. 
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